Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules

PURPOSE: To identify sunitinib alternative schedules (AS) that maintained dose intensity while decreasing adverse events (AEs) in patients with metastatic renal cell cancer (mRCC), and to determine impact of AS on clinical outcomes. PATIENTS AND METHODS: A retrospective review of patients ≥ 18 yr of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Atkinson, Bradley J., Kalra, Sarathi, Wang, Xuemei, Bathala, Tharakeswara, Corn, Paul, Tannir, Nizar M., Jonasch, Eric
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015627/
https://ncbi.nlm.nih.gov/pubmed/24018239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2013.08.090
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi